Haemonetics/$HAE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Haemonetics
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Ticker
$HAE
Sector
Primary listing
NYSE
Employees
3,023
Headquarters
Website
Haemonetics Metrics
BasicAdvanced
$2.4B
15.26
$3.28
0.39
-
Price and volume
Market cap
$2.4B
Beta
0.39
52-week high
$91.45
52-week low
$47.32
Average daily volume
706K
Financial strength
Current ratio
1.718
Quick ratio
0.931
Long term debt to equity
104.424
Total debt to equity
138.874
Interest coverage (TTM)
6.53%
Profitability
EBITDA (TTM)
369.568
Gross margin (TTM)
58.77%
Net profit margin (TTM)
12.13%
Operating margin (TTM)
19.39%
Effective tax rate (TTM)
22.42%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
6.52%
Return on equity (TTM)
18.27%
Valuation
Price to earnings (TTM)
15.261
Price to revenue (TTM)
1.844
Price to book
2.73
Price to tangible book (TTM)
-13.71
Price to free cash flow (TTM)
13.119
Free cash flow yield (TTM)
7.62%
Free cash flow per share (TTM)
3.812
Growth
Revenue change (TTM)
0.91%
Earnings per share change (TTM)
46.89%
3-year revenue growth (CAGR)
9.47%
10-year revenue growth (CAGR)
4.12%
3-year earnings per share growth (CAGR)
35.85%
10-year earnings per share growth (CAGR)
24.03%
What the Analysts think about Haemonetics
Analyst ratings (Buy, Hold, Sell) for Haemonetics stock.
Bulls say / Bears say
Adjusted gross margin expanded by 620 basis points YoY to 60.2% in Q4 FY25, reflecting effective cost discipline and strategic portfolio transformation. (MarketScreener)
Hospital segment revenue grew 12.2% YoY in Q4 FY25 to $147.9 million, driven by strong adoption of high-margin products like the NexSys blood processing and TEG hemostasis platforms. (Ainvest)
Management executed a $150 million share repurchase program and authorized a new $500 million buyback in Q4 FY25, underscoring confidence in the company’s long-term growth and commitment to shareholder returns. (Ainvest)
Fourth quarter FY25 net revenue declined 3.7% YoY to $330.6 million, highlighting persistent top-line headwinds despite operating leverage. (MarketScreener)
Plasma segment revenue fell 9.1% YoY to $126.7 million in Q4 FY25, driven by the CSL Plasma contract transition, exposing customer concentration risk. (MarketScreener)
Blood Center segment revenue plunged 22.2% YoY to $56.0 million in Q4 FY25 following the whole blood business divestiture, weakening revenue diversification. (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Haemonetics Financial Performance
Revenues and expenses
Haemonetics Earnings Performance
Company profitability
Haemonetics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Haemonetics stock?
Haemonetics (HAE) has a market cap of $2.4B as of November 02, 2025.
What is the P/E ratio for Haemonetics stock?
The price to earnings (P/E) ratio for Haemonetics (HAE) stock is 15.26 as of November 02, 2025.
Does Haemonetics stock pay dividends?
No, Haemonetics (HAE) stock does not pay dividends to its shareholders as of November 02, 2025.
When is the next Haemonetics dividend payment date?
Haemonetics (HAE) stock does not pay dividends to its shareholders.
What is the beta indicator for Haemonetics?
Haemonetics (HAE) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.